The licensing deal covers a combination drug, using Zertane and another erectile dysfunction drug (PDE5 inhibitors and others), to simultaneously treat premature ejaculation and erectile dysfunction (ED).
The agreement allows Ampio to get multi million dollar upfront, regulatory and sales related milestone payments to Daewoong, and a royalty stream equal to 25% of net sales less Ampio’s transfer price.
Additionalyy, Daewoong will also fund a full Phase III clinical trial for Ampio’s follow on combination PE/ED drug.
Ampio CEO Don Wingerter said as Zertane is patent protected in 32 countries, the company is pursuing similar agreements with additional regional partners, some of whom already have market approval for the active ingredient of Zertane in various formulations, thereby accelerating time to market.